[ ¹¹ C]PS13 Demonstrates Pharmacologically Selective and Substantial Binding to Cyclooxygenase-1 in the Human Brain.

Autor: Ghazanfari N; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland., Liow JS; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland., Kim MJ; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.; Stony Brook University School of Medicine, Stony Brook, New York., Cureton R; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland., Lee A; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland., Knoer C; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland., Jenkins M; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland., Hong J; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland., Santamaria JAM; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland., Shetty HU; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland., Galassi A; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland., Wighton P; Athinoula A. Martinos Center for Biomedical Imaging, Boston, Massachusetts; and., Nørgaard M; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.; University of Copenhagen, Copenhagen, Denmark., Greve DN; Athinoula A. Martinos Center for Biomedical Imaging, Boston, Massachusetts; and., Zoghbi SS; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland., Pike VW; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland., Innis RB; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland; robert.innis@nih.gov., Zanotti-Fregonara P; Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Nov 14. Date of Electronic Publication: 2024 Nov 14.

First-in-Human Evaluation of ¹⁸ F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4B.

Autor: Wakabayashi Y; Molecular Imaging Branch, NIMH-NIH, Bethesda, Maryland., Stenkrona P; Department of Clinical Neuroscience Psychiatry Section, Karolinska Institutet, Stockholm, Sweden., Arakawa R; Department of Clinical Neuroscience Psychiatry Section, Karolinska Institutet, Stockholm, Sweden., Yan X; Molecular Imaging Branch, NIMH-NIH, Bethesda, Maryland., Van Buskirk MG; Molecular Imaging Branch, NIMH-NIH, Bethesda, Maryland., Jenkins MD; Molecular Imaging Branch, NIMH-NIH, Bethesda, Maryland., Santamaria JAM; Molecular Imaging Branch, NIMH-NIH, Bethesda, Maryland., Maresca KP; Worldwide Research, Development, and Medicine, Pfizer Inc., New York, New York; and., Takano A; Department of Clinical Neuroscience Psychiatry Section, Karolinska Institutet, Stockholm, Sweden., Liow JS; Molecular Imaging Branch, NIMH-NIH, Bethesda, Maryland., Chappie TA; Worldwide Research, Development, and Medicine, Pfizer Inc., New York, New York; and., Varrone A; Department of Clinical Neuroscience Psychiatry Section, Karolinska Institutet, Stockholm, Sweden., Nag S; Department of Clinical Neuroscience Psychiatry Section, Karolinska Institutet, Stockholm, Sweden., Zhang L; Worldwide Research, Development, and Medicine, Pfizer Inc., New York, New York; and., Hughes ZA; Worldwide Research, Development, and Medicine, Pfizer Inc., New York, New York; and., Schmidt CJ; Worldwide Research, Development, and Medicine, Pfizer Inc., New York, New York; and., Doran SD; Worldwide Research, Development, and Medicine, Pfizer Inc., New York, New York; and., Mannes A; Anesthesia Department, NIH Clinical Center, Bethesda, Maryland., Zanotti-Fregonara P; Molecular Imaging Branch, NIMH-NIH, Bethesda, Maryland., Ooms M; Molecular Imaging Branch, NIMH-NIH, Bethesda, Maryland., Morse CL; Molecular Imaging Branch, NIMH-NIH, Bethesda, Maryland., Zoghbi SS; Molecular Imaging Branch, NIMH-NIH, Bethesda, Maryland., Halldin C; Department of Clinical Neuroscience Psychiatry Section, Karolinska Institutet, Stockholm, Sweden., Pike VW; Molecular Imaging Branch, NIMH-NIH, Bethesda, Maryland., Innis RB; Molecular Imaging Branch, NIMH-NIH, Bethesda, Maryland; robert.innis@nih.gov.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2022 Dec; Vol. 63 (12), pp. 1919-1924. Date of Electronic Publication: 2022 Jun 30.